Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.

Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the coming five years to bolster its presence ...

CDMOs are crucial partners in alum-based vaccine production, managing aseptic filling with precision and efficiency.